Terrapinn's world influenza congress Europe 2009. Part 2.
Terrapinn's World Influenza Congress Europe 2009, held in Brussels, included topics covering new developments in the field of influenza vaccination. This conference report highlights selected presentations on the use of novel technologies for developing vaccines for influenza. Investigational vaccines discussed include Multimeric-001 (BiondVax Pharmaceuticals Ltd), NB-1008 (NanoBio Corp) and an influenza vaccine containing the CAF-01 adjuvant (Statens Serum Institut).
Veryard
Claire
C
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. claire.veryard@thomsonreuters.com
D000818:Animals; D002986:Clinical Trials as Topic; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D013678:Technology, Pharmaceutical / Q000379:methods
D015507:Drugs, Investigational; D007252:Influenza Vaccines